Advertisement

The Effects of Selective Complement and CD14 Inhibition on the E. coli-Induced Tissue Factor mRNA Upregulation, Monocyte Tissue Factor Expression, and Tissue Factor Functional Activity in Human Whole Blood

  • O.-L. Brekke
  • C. Waage
  • D. Christiansen
  • H. Fure
  • H. Qu
  • John D. Lambris
  • B. Østerud
  • E. W. Nielsen
  • T. E. MollnesEmail author
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 735)

Abstract

Background: The complement pathway and CD14 play essential roles in inflammation, but little is known about the relative roles of complement and CD14 in E. coli-induced tissue factor (TF) mRNA upregulation, expression by monocytes, and functional activity in human whole blood. Methods: Whole E. coli bacteria were incubated for up to 4 h in human whole blood containing the anticoagulant lepirudin, which does not affect complement activation. TF mRNA levels were analyzed using reverse transcription, quantitative real-time PCR (RT-qPCR), and the expression of TF on the cell surface was analyzed using flow cytometry. Complement was selectively inhibited using the C3 convertase inhibitor compstatin or a C5a receptor antagonist (C5aRa), while CD14 was blocked by an anti-CD14 F(ab′)2 monoclonal antibody. Results: The E. coli-induced TF mRNA upregulation was reduced to virtually background levels by compstatin, whereas anti-CD14 had no effect. Monocyte TF expression and TF activity in plasma microparticles were significantly reduced by C5aRa. Anti-CD14 alone only slightly reduced E. coli-induced monocyte TF expression but showed a modest additive effect when combined with the complement inhibitors. Inhibiting complement and CD14 efficiently reduced the expression of the E. coli-induced cytokines IL-1β, IL-6, IL-8, and platelet-derived growth factor bb. Conclusion: Our results indicate that E. coli-induced TF mRNA upregulation is mainly dependent on complement activation, while CD14 plays a modest role in monocyte TF expression and the plasma TF activity in human whole blood.

Keywords

Tissue Factor Tissue Factor Expression Median Fluorescence Intensity Tissue Factor Activity Tissue Factor mRNA 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The technical assistance of Grethe Bergseth is greatly acknowledged. This work was supported by NIH grants AI-068730 and GM 62134 and grants from Helse Nord RHF.

Conflict of Interest Statement The author Professor J.D. Lambris has submitted several patent applications on ­complement inhibitors. None of the other authors have conflicts of interest.

References

  1. Brandtzaeg P, Mollnes TE, Kierulf P (1989) Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 160(1):58–65PubMedCrossRefGoogle Scholar
  2. Brekke OL, Christiansen D, Fure H, Fung M, Mollnes TE (2007) The role of complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood. J Leukoc Biol 81(6):1404–1413PubMedCrossRefGoogle Scholar
  3. Brekke OL, Christiansen D, Fure H, Pharo A, Fung M, Riesenfeld J et al (2008) Combined inhibition of complement and CD14 abolish E. coli-induced cytokine-, chemokine- and growth factor-synthesis in human whole blood. Mol Immunol 45(14):3804–3813PubMedCrossRefGoogle Scholar
  4. Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407(6801):258–264PubMedCrossRefGoogle Scholar
  5. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA (2005) Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 106(5):1604–1611PubMedCrossRefGoogle Scholar
  6. Eligini S, Brambilla M, Banfi C, Camera M, Sironi L, Barbieri SS et al (2002) Oxidized phospholipids inhibit cyclooxygenase-2 in human macrophages via nuclear factor-kappaB/IkappaB- and ERK2-dependent mechanisms. Cardiovasc Res 55(2):406–415PubMedCrossRefGoogle Scholar
  7. Engstad CS, Lia K, Rekdal O, Olsen JO, Osterud B (1995) A novel biological effect of platelet factor 4 (PF4): enhancement of LPS-induced tissue factor activity in monocytes. J Leukoc Biol 58(5):575–581PubMedCrossRefGoogle Scholar
  8. Ernofsson M, Siegbahn A (1996) Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor. Thromb Res 83(4):307–320PubMedCrossRefGoogle Scholar
  9. Ernofsson M, Tenno T, Siegbahn A (1996) Inhibition of tissue factor surface expression in human peripheral blood monocytes exposed to cytokines. Br J Haematol 95(2):249–257PubMedCrossRefGoogle Scholar
  10. Gabay C, Lamacchia C, Palmer G (2010) IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6(4):232–241PubMedCrossRefGoogle Scholar
  11. Gregory SA, Morrissey JH, Edgington TS (1989) Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 9(6):2752–2755PubMedPubMedCentralCrossRefGoogle Scholar
  12. Henriksson CE, Klingenberg O, Ovstebo R, Joo GB, Westvik AB, Kierulf P (2005) Discrepancy between tissue factor activity and tissue factor expression in endotoxin-induced monocytes is associated with apoptosis and necrosis. Thromb Haemost 94(6):1236–1244PubMedGoogle Scholar
  13. Hiller E, Saal JG, Riethmuller G (1977) Procoagulant activity of activated monocytes. Haemostasis 6(6):347–350PubMedGoogle Scholar
  14. Huber-Lang MS, Riedeman NC, Sarma JV, Younkin EM, McGuire SR, Laudes IJ et al (2002) Protection of innate immunity by C5aR antagonist in septic mice. FASEB J 16(12):1567–1574PubMedCrossRefGoogle Scholar
  15. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR et al (2006) Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 12(6):682–687PubMedCrossRefGoogle Scholar
  16. Janssen BJ, Halff EF, Lambris JD, Gros P (2007) Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J Biol Chem 282(40):29241–29247PubMedCrossRefGoogle Scholar
  17. Kambas K, Markiewski M, Pneumatikos I, Rafail S, Theodorou V, Konstantonis D et al (2008) C5a and TNF-alpha up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome. J Immunol 180:7368–7375PubMedPubMedCentralCrossRefGoogle Scholar
  18. Kappelmayer J, Bernabei A, Edmunds LH Jr, Edgington TS, Colman RW (1993) Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res 72(5):1075–1081PubMedCrossRefGoogle Scholar
  19. Katragadda M, Magotti P, Sfyroera G, Lambris JD (2006) Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem 49(15):4616–4622PubMedCrossRefGoogle Scholar
  20. Lappegard KT, Christiansen D, Pharo A, Thorgersen EB, Hellerud BC, Lindstad J et al (2009) Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc Natl Acad Sci USA 106:15861–15866PubMedCrossRefGoogle Scholar
  21. Levi M, de Jonge E, van der Poll T (2006) Plasma and plasma components in the management of disseminated intravascular coagulation. Best Pract Res Clin Haematol 19(1):127–142PubMedCrossRefGoogle Scholar
  22. Lyberg T, Prydz H (1982) Thromboplastin (factor III) activity in human monocytes induced by immune complexes. Eur J Clin Invest 12(3):229–234PubMedCrossRefGoogle Scholar
  23. Mackman N (2009) The many faces of tissue factor. J Thromb Haemost 7(Suppl 1):136–139PubMedPubMedCentralCrossRefGoogle Scholar
  24. Malarstig A, Siegbahn A (2007) The intersubject variability of tissue factor mRNA production in human monocytes–relation with the toll-like receptor 4. Thromb Res 120(3):407–413PubMedCrossRefGoogle Scholar
  25. Meszaros K, Aberle S, Dedrick R, Machovich R, Horwitz A, Birr C et al (1994) Monocyte tissue factor induction by lipopolysaccharide (LPS): dependence on LPS-binding protein and CD14, and inhibition by a recombinant fragment of bactericidal/permeability-increasing protein. Blood 83(9):2516–2525PubMedGoogle Scholar
  26. Mohan Rao LV, Mackman N (2010) Factor VIIa and tissue factor – from cell biology to animal models. Thromb Res 125(S1):S1–S3Google Scholar
  27. Mollnes TE, Lea T, Froland SS, Harboe M (1985) Quanepsication of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 22(2):197–202PubMedCrossRefGoogle Scholar
  28. Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G et al (2002) Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100(5):1869–1877PubMedPubMedCentralGoogle Scholar
  29. Nakae H, Endo S, Inada K, Yoshida M (1996) Chronological changes in the complement system in sepsis. Surg Today 26(4):225–229PubMedCrossRefGoogle Scholar
  30. Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD (2007) The role of complement in biomaterial-induced inflammation. Mol Immunol 44(1–3):82–94PubMedCrossRefGoogle Scholar
  31. Oeth PA, Parry GC, Kunsch C, Nantermet P, Rosen CA, Mackman N (1994) Lipopolysaccharide induction of tissue factor gene expression in monocytic cells is mediated by binding of c-Rel/p65 heterodimers to a kappa B-like site. Mol Cell Biol 14(6):3772–3781PubMedPubMedCentralCrossRefGoogle Scholar
  32. Osnes LT, Westvik AB, Joo GB, Okkenhaug C, Kierulf P (1996) Inhibition of IL-1 induced tissue factor (TF) synthesis and procoagulant activity (PCA) in purified human monocytes by IL-4, IL-10 and IL-13. Cytokine 8(11):822–827PubMedCrossRefGoogle Scholar
  33. Osterud B (1995) Cellular interactions in tissue factor expression by blood monocytes. Blood Coagul Fibrinolysis 6(Suppl 1):S20–S25PubMedCrossRefGoogle Scholar
  34. Osterud B, Olsen JO, Benjaminsen AW (1984) The role of complement in the induction of thromboplastin synthesis. Haemostasis 14(5):386–392PubMedGoogle Scholar
  35. Osterud B, Breimo ES, Olsen JO (2008) Blood borne tissue factor revisited. Thromb Res 122(3):432–434PubMedCrossRefGoogle Scholar
  36. Prydz H, Allison AC, Schorlemmer HU (1977) Further link between complement activation and blood coagulation. Nature 270(5633):173–174PubMedCrossRefGoogle Scholar
  37. Riedemann NC, Guo RF, Ward PA (2003) A key role of C5a/C5aR activation for the development of sepsis. J Leukoc Biol 74(6):966–970PubMedCrossRefGoogle Scholar
  38. Sahu A, Kay BK, Lambris JD (1996) Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol 157(2):884–891PubMedGoogle Scholar
  39. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC et al (1990) Structure and function of lipopolysaccharide binding protein. Science 249(4975):1429–1431PubMedCrossRefGoogle Scholar
  40. Siegbahn A (2000) Cellular consequences upon factor VIIa binding to tissue factor. Haemostasis 30(Suppl 2):41–47PubMedGoogle Scholar
  41. Siegbahn A, Johnell M, Sorensen BB, Petersen LC, Heldin CH (2005) Regulation of chemotaxis by the cytoplasmic domain of tissue factor. Thromb Haemost 93(1):27–34PubMedCrossRefGoogle Scholar
  42. Steinemann S, Ulevitch RJ, Mackman N (1994) Role of the lipopolysaccharide (LPS)-binding protein/CD14 pathway in LPS induction of tissue factor expression in monocytic cells. Arterioscler Thromb 14(7):1202–1209PubMedCrossRefGoogle Scholar
  43. Strey CW, Markiewski M, Mastellos D, Tudoran R, Spruce LA, Greenbaum LE et al (2003) The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med 198(6):913–923PubMedPubMedCentralCrossRefGoogle Scholar
  44. Van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA (2011) Inflammasome activation and IL-1beta and IL-18 processing during infection. Trends Immunol 32(3):110–116PubMedCrossRefGoogle Scholar
  45. Ward PA (2004) The dark side of C5a in sepsis. Nat Rev Immunol 4(2):133–142PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • O.-L. Brekke
    • 1
    • 2
  • C. Waage
    • 1
    • 2
  • D. Christiansen
    • 1
    • 2
  • H. Fure
    • 1
    • 2
  • H. Qu
    • 1
    • 2
  • John D. Lambris
    • 1
    • 2
  • B. Østerud
    • 1
    • 2
  • E. W. Nielsen
    • 1
    • 2
  • T. E. Mollnes
    • 1
    • 2
    Email author
  1. 1.Department of Laboratory MedicineNordland HospitalBodøNorway
  2. 2.Institute of Medical BiologyUniversity of TromsøTromsøNorway

Personalised recommendations